1
|
Crespo-Sanjuán J, Calvo-Nieves MD, Aguirre-Gervás B, Herreros-Rodríguez J, Velayos-Jiménez B, Castro-Alija MJ, Muñoz-Moreno MF, Sánchez D, Zamora-González N, Bajo-Grañeras R, García-Centeno RM, Largo Cabrerizo ME, Bustamante MR, Garrote-Adrados JA. Early detection of high oxidative activity in patients with adenomatous intestinal polyps and colorectal adenocarcinoma: myeloperoxidase and oxidized low-density lipoprotein in serum as new markers of oxidative stress in colorectal cancer. Lab Med 2016; 46:123-35. [PMID: 25918191 DOI: 10.1309/lmzjju6bc86wudhw] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
OBJECTIVES To detect whether signs of oxidative stress appear at early stages of colorectal adenocarcinoma (CRC), particularly in the polyp stage. We also aimed to evaluate the specific entities myeloperoxidase (MPO) and oxidized low-density lipoprotein (oxLDL) as novel markers of oxidation in the plasma of patients with CRC and to study the relationship between oxidative status in plasma and patient survival. METHODS We assayed serum or plasma specimens from healthy control subjects (n = 14), from patients with intestinal polyps (n = 39), and from patients with CRC (n = 128) to calculate the modified oxidative balance score (MOBS) using several serum markers (β-carotene, lycopene, vitamin A, vitamin E, MPO, and oxLDL). We also assayed the levels of C-reactive protein (CRP) and obtained lipid profiles. Finally, we studied the survival of patients in relationship to oxidative status (antioxidants and pro-oxidants) and inflammation markers, and added theses data to the lipid profile for each patient. RESULTS Oxidative stress levels increased as disease stage advanced. This increase was detected early in the polyp stage, before polyps progressed to cancer, and could be measured by the increase of such new markers as MPO and oxLDL, the decrease in antioxidants, and the MOBS value. Higher levels of oxidation correlated with lower survival. CONCLUSION The oxidation process, which can cause mutations leading to CRC, begins development in the polyp stage. This process may be detected early by monitoring serum markers such as MPO and oxLDL.
Collapse
Affiliation(s)
- Jesús Crespo-Sanjuán
- Department of Clinical Laboratory, Clinical Hospital, University of Valladolid, Valladolid, Spain
| | - María D Calvo-Nieves
- Department of Clinical Laboratory, Clinical Hospital, University of Valladolid, Valladolid, Spain
| | - Beatriz Aguirre-Gervás
- Department of Clinical Laboratory, Clinical Hospital, University of Valladolid, Valladolid, Spain
| | - José Herreros-Rodríguez
- Department of Clinical Laboratory, Clinical Hospital, University of Valladolid, Valladolid, Spain
| | - Benito Velayos-Jiménez
- Department of Clinical Laboratory, Clinical Hospital, University of Valladolid, Valladolid, Spain
| | - María J Castro-Alija
- Department of Nutrition, School of Medicine, University of Valladolid, Valladolid, Spain
| | - María F Muñoz-Moreno
- Department of Clinical Laboratory, Clinical Hospital, University of Valladolid, Valladolid, Spain
| | - Diego Sánchez
- Department of Biochemistry, Molecular Biology, and Physiology, Biology and Genetics Institute, University of Valladolid-Superior Council of Scientific Investigations (CSIC), Valladolid, Spain
| | - Nuria Zamora-González
- Department of Clinical Laboratory, Clinical Hospital, University of Valladolid, Valladolid, Spain
| | - Raquel Bajo-Grañeras
- Department of Biochemistry, Molecular Biology, and Physiology, Biology and Genetics Institute, University of Valladolid-Superior Council of Scientific Investigations (CSIC), Valladolid, Spain
| | - Rosa M García-Centeno
- Department of Clinical Laboratory, Clinical Hospital, University of Valladolid, Valladolid, Spain
| | - María E Largo Cabrerizo
- Department of Clinical Laboratory, Clinical Hospital, University of Valladolid, Valladolid, Spain
| | - María R Bustamante
- Department of Clinical Laboratory, Clinical Hospital, University of Valladolid, Valladolid, Spain
| | | |
Collapse
|
2
|
Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications. BMC Surg 2013; 13:43. [PMID: 24073705 PMCID: PMC3849728 DOI: 10.1186/1471-2482-13-43] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2013] [Accepted: 09/24/2013] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Neoadjuvant radiochemotherapy has proven superior to adjuvant treatment in reducing the rate of local recurrence without impairing cancer related survival or the incidence of distant metastases. The present study aimed at addressing the effects of an intensified protocol of neoadjuvant treatment on the development of postoperative complications. METHODS A total of 387 patients underwent oncological resection for rectal cancer in our institution between January 2000 and December 2009. 106 patients received an intensified radiochemotherapy. Perioperative morbidity and mortality were analyzed retrospectively with special attention on complication rates after intensified radio-chemotherapy. Therefore, for each patient subjected to neoadjuvant treatment a patient without neoadjuvant treatment was matched in the following order for tumor height, discontinuous resection/exstirpation, T-category of the TNM-system, dividing stoma and UICC stage. RESULTS Of all patients operated for rectal cancer, 27.4% received an intensified neoadjuvant treatment. Tumor location in the matched patients were in the lower third (55.2%), middle third (41.0%) and upper third (3.8%) of the rectum. Postoperatively, surgical morbidity was higher after intensified neoadjuvant treatment. In the subgroup with low anterior resection (LAR) the anastomosis leakage rate was higher (26.6% vs. 9.7%) and in the subgroup of patients with rectal exstirpations the perineal wound infection rate was increased (42.2% vs. 18.8%) after intensified radiochemotherapy. CONCLUSIONS In rectal cancer the decision for an intensified neoadjuvant treatment comes along with an increase of anastomotic leakage and perineal wound infection. Quality of life is often reduced considerably and has to be balanced against the potential benefit of intensifying neoadjuvant radiochemotherapy.
Collapse
|
3
|
Schiffmann L, Klautke G, Wedermann N, Gock M, Prall F, Fietkau R, Rau B, Klar E. Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy - a matched pair analysis. BMC Cancer 2013; 13:388. [PMID: 23947828 PMCID: PMC3765433 DOI: 10.1186/1471-2407-13-388] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2013] [Accepted: 08/09/2013] [Indexed: 12/17/2022] Open
Abstract
Background Neoadjuvant radiochemotherapy has been proven superior to adjuvant treatment in reducing the rate of local recurrence without impairing cancer related survival or the incidence of distant metastases in standard protocols of neoadjuvant radiochemotherapy. The present study aimed at addressing the effects of an intensified neoadjuvant radiochemotherapy on long term cancer related and disease free survival. Methods A total of 387 patients underwent oncologic resection for rectal cancer in our institution between January 2000 and December 2009. There were 106 patients (27.4%) who received an intensified radiochemotherapy protocol completely and without excluding criteria (study group). A matched pair analysis was performed by comparing the study group with patients undergoing primary surgery and postoperative radiochemotherapy, if necessary and possible (control group). Matching was carried out in descending order for UICC stage, R-status, tumor height, T-, N-, V-, L-, M- and G-category of the TNM-system according to the histopathological staging. Follow-up data included local recurrence rate, cancer related and disease free survival. Results In the study group histopathological work-up of the specimen revealed a treatment response in terms of tumor regression in 92.5% (98/106) of these patients. Undergoing intensified neoadjuvant RCT the actuarial cancer related and disease free survival was 67.9% and 70.4%, local recurrence was 5.7% after an observation period of 4.3 ± 2.55 years. In the control group cancer related and disease free survival was 71.7% and 82.7%, local recurrence was 4.7% after an observation period of 3.8 ± 3.05 years revealing no statistical significant difference between the two groups. Moreover, estimated 5-year results of cancer related survival (66.7% vs 67.9% (controls)), the disease free survival (66.7% vs 79.9% (controls)) as well as subgroup analysis of UICC 0-III and UICC IV patients showed no difference between the study and control group as well. Conclusion In our study, intensified neoadjuvant radio-chemotherapy shows a high rate of tumor regression. The resulting inferior histopathological tumor stage shows the same long term local control and systemic tumor control as the control group with a primary more favorable tumor stage.
Collapse
|